Search

Your search keyword '"Dutch Upper GI Canc Grp"' showing total 2 results
Start Over Author "Dutch Upper GI Canc Grp"
2 results on '"Dutch Upper GI Canc Grp"'

1. Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: Analysis from the population-based POCOP study

Author

Dutch Upper GI Canc Grp DUCG, van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G-J, Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., van Laarhoven, H. W. M., Dutch Upper GI Canc Grp DUCG, van Kleef, J. J., Dijksterhuis, W. P. M., van den Boorn, H. G., Prins, M., Verhoeven, R. H. A., Gisbertz, S. S., Slingerland, M., Mohammad, N. Haj, Creemers, G-J, Neelis, K. J., Heisterkamp, J., Rosman, C., Ruurda, J. P., Kouwenhoven, E. A., van de Poll-Franse, L. V., van Oijen, M. G. H., Sprangers, M. A. G., and van Laarhoven, H. W. M.

Abstract

Background Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover, differences in disease stages and tumour-specific symptoms are usually not taken into consideration. The aim of this population-based study was to assess the prognostic value of HRQoL, including tumour-specific scales, on OS in patients with potentially curable and advanced oesophagogastric cancer. Methods Data were derived from the Netherlands Cancer Registry and the patient reported outcome registry (POCOP). Patients included in POCOP between 2016 and 2018 were stratified for potentially curable (cT1-4aNallM0) or advanced (cT4b or cM1) disease. HRQoL was measured with the EORTC QLQ-C30 and the tumour-specific OG25 module. Cox proportional hazards models assessed the impact of HRQoL, sociodemographic and clinical factors (including treatment) on OS. Results In total, 924 patients were included. Median OS was 38.9 months in potentially curable patients (n = 795) and 10.6 months in patients with advanced disease (n = 129). Global Health Status was independently associated with OS in potentially curable patients (HR 0.89, 99%CI 0.82-0.97), together with several other HRQoL items: appetite loss, dysphagia, eating restrictions, odynophagia, and body image. In advanced disease, the Summary Score was the strongest independent prognostic factor (HR 0.75, 99%CI 0.59-0.94), followed by fatigue, pain, insomnia and role functioning. Conclusion In a real-world setting, HRQoL was prognostic for OS in patients with potentially curable and advanced oesophagogastric cancer. Several HRQoL domains, including the Summary Score and several OG25 items, could be used to develop or update prognostic models.

Published
2021

2. Nationwide comprehensive gastro-intestinal cancer cohorts

Author

Braak, R.R.J.C. van den, Rijssen, L.B. van, Kleef, J.J. van, Vink, G.R., Berbee, M., Henegouwen, M.I.V., Bloemendal, H.J., Bruno, M.J., Burgmans, M.C., Busch, O.R.C., Coene, P.P.L.O., Coupe, V.M.H., Dekker, J.W.T., Eijck, C.H.J. van, Elferink, M.A.G., Erdkamp, F.L.G., Grevenstein, W.M.U. van, Groot, J.W.B. de, Grieken, N.C.T. van, Hingh, I.H.J.T. de, Hulshof, M.C.C.M., Ijzermans, J.N.M., Kwakkenbos, L., Lemmens, V.E.P.P., M. los, Meijer, G.A., Molenaar, I.Q., Nieuwenhuijzen, G.A.P., Noo, M.E. de, Poll-Franse, L.V. van de, Punt, C.J.A., Rietbroek, R.C., Roeloffzen, W.W.H., Rozema, T., Ruurda, J.P., Sandick, J.W. van, Schiphorst, A.H.W., Schipper, H., Siersema, P.D., Slingerland, M., Sommeijer, D.W., Spaander, M.C.W., Sprangers, M.A.G., Stockmann, H.B.A.C., Strijker, M., Tienhoven, G. van, Timmermans, L.M., Tjin-a-Ton, M.L.R., Velden, A.M.T. van der, Verhaar, M.J., Verkooijen, H.M., Vles, W.J., Vos-Geelen, J.M.P.G.M. de, Wilmink, J.W., Zimmerman, D.D.E., Oijen, M.G.H. van, Koopman, M., Besselink, M.G.H., Laarhoven, H.W.M. van, Dutch Pancreatic Canc Grp, Dutch Upper GI Canc Grp, PLCRC Working Grp, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Promovendi ODB, MUMC+: MA Radiotherapie OC (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), CCA - Cancer Treatment and quality of life, APH - Methodology, Epidemiology and Data Science, AGEM - Re-generation and cancer of the digestive system, Pathology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Surgery, Graduate School, Radiotherapy, Oncology, APH - Aging & Later Life, APH - Mental Health, Medical Psychology, APH - Quality of Care, Gastroenterology & Hepatology, Public Health, Erasmus MC other, and Medical and Clinical Psychology

Subjects
0301 basic medicine, medicine.medical_specialty, INFRASTRUCTURE, law.invention, COLORECTAL-CANCER, Cohort Studies, Experimental Psychopathology and Treatment, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Randomized controlled trial, SDG 3 - Good Health and Well-being, DESIGN, law, Informed consent, MOLECULAR SUBTYPES, medicine, Humans, QUALITY, Radiology, Nuclear Medicine and imaging, Registries, Biological Specimen Banks, Gastrointestinal Neoplasms, Randomized Controlled Trials as Topic, ESOPHAGEAL, INFORMED-CONSENT, business.industry, Clinical study design, Cancer, Hematology, General Medicine, medicine.disease, Surgery, Cancer registry, Clinical trial, Observational Studies as Topic, 030104 developmental biology, Oncology, Research Design, 030220 oncology & carcinogenesis, Cohort, Emergency medicine, business, CLINICAL-TRIALS, Cohort study
Abstract

Contains fulltext : 190038.pdf (Publisher’s version ) (Open Access) Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting. 8 p.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results